Oriol Yélamos1, Cristián Navarrete-Dechent2, Michael A Marchetti3, Tova Rogers3, Zoe Apalla4, Philippe Bahadoran5, Nuria Blázquez-Sánchez6, Klaus Busam7, Cristina Carrera8, Stephen W Dusza3, Arnaud de la Fouchardière9, Gerardo Ferrara10, Pedram Gerami11, Harald Kittler12, Aimilios Lallas4, Josep Malvehy8, José F Millán-Cayetano6, Kelly C Nelson13, Victor Li Quan11, Susana Puig8, Howard Stevens14, Luc Thomas15, Ashfaq A Marghoob3. 1. Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, and CIBER de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain. Electronic address: oyelamos@gmail.com. 2. Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Dermatology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. 3. Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 4. First Department of Dermatology, Aristotle University, Thessaloniki, Greece. 5. Dermatology Department, Centre Hospitalier Universitaire de Nice, Nice, France. 6. Dermatology Department, Hospital Costa del Sol, Marbella, Spain. 7. Pathology Department, Memorial Sloan Kettering Cancer Center, New York, New York. 8. Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, and CIBER de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain. 9. Département de Biopathologie, Centre Léon Bérard, Lyon, France. 10. Anatomic Pathology Unit, Hospital of Macerata, Macerata, Italy. 11. Dermatology Department, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 12. Department of Dermatology, Medical University of Vienna, Vienna, Austria. 13. Dermatology Department, The University of Texas MD Anderson Cancer Center, Houston, Texas. 14. Skin Care Network, Barnet, London, United Kingdom. 15. Department of Dermatology, Lyon 1 University, Centre Hospitalier Lyon Sud and Lyon's Cancer Research Center INSERM U1052 - CNRS UMR5286, Lyon, France.
Abstract
BACKGROUND: Multiple BRCA1-associated protein 1 (BAP1)-inactivated melanocytic tumors (BIMTs) have been associated with a familial cancer syndrome involving germline mutations in BAP1. OBJECTIVES: We sought to describe the clinical and dermoscopic features of BIMTs. METHODS: This was a retrospective, multicenter, case-control study. Participating centers contributed clinical data, dermoscopic images, and histopathologic data of biopsy-proven BIMTs. We compared the dermoscopic features between BIMTs and control patients. RESULTS: The dataset consisted of 48 BIMTs from 31 patients (22 women; median age 37 years) and 80 control patients. Eleven patients had a BAP1 germline mutation. Clinically, most BIMTs presented as pink, dome-shaped papules (n = 24). Dermoscopically, we identified 5 patterns: structureless pink-to-tan with irregular eccentric dots/globules (n = 14, 29.8%); structureless pink-to-tan with peripheral vessels (n = 10, 21.3%); structureless pink-to-tan (n = 7, 14.9%); a network with raised, structureless, pink-to-tan areas (n = 7, 14.9%); and globular pattern (n = 4, 8.5%). The structureless with eccentric dots/globules pattern and network with raised structureless areas pattern were only identified in BIMT and were more common in patients with BAP1 germline mutations (P < .0001 and P = .001, respectively). LIMITATIONS: Limitations included our small sample size, retrospective design, the absence of germline genetic testing in all patients, and inclusion bias toward more atypical-looking BIMTs. CONCLUSIONS: Dome-shaped papules with pink-to-tan structureless areas and peripheral irregular dots/globules or network should raise the clinical suspicion for BIMT.
BACKGROUND: Multiple BRCA1-associated protein 1 (BAP1)-inactivated melanocytic tumors (BIMTs) have been associated with a familial cancer syndrome involving germline mutations in BAP1. OBJECTIVES: We sought to describe the clinical and dermoscopic features of BIMTs. METHODS: This was a retrospective, multicenter, case-control study. Participating centers contributed clinical data, dermoscopic images, and histopathologic data of biopsy-proven BIMTs. We compared the dermoscopic features between BIMTs and control patients. RESULTS: The dataset consisted of 48 BIMTs from 31 patients (22 women; median age 37 years) and 80 control patients. Eleven patients had a BAP1 germline mutation. Clinically, most BIMTs presented as pink, dome-shaped papules (n = 24). Dermoscopically, we identified 5 patterns: structureless pink-to-tan with irregular eccentric dots/globules (n = 14, 29.8%); structureless pink-to-tan with peripheral vessels (n = 10, 21.3%); structureless pink-to-tan (n = 7, 14.9%); a network with raised, structureless, pink-to-tan areas (n = 7, 14.9%); and globular pattern (n = 4, 8.5%). The structureless with eccentric dots/globules pattern and network with raised structureless areas pattern were only identified in BIMT and were more common in patients with BAP1 germline mutations (P < .0001 and P = .001, respectively). LIMITATIONS: Limitations included our small sample size, retrospective design, the absence of germline genetic testing in all patients, and inclusion bias toward more atypical-looking BIMTs. CONCLUSIONS: Dome-shaped papules with pink-to-tan structureless areas and peripheral irregular dots/globules or network should raise the clinical suspicion for BIMT.
Authors: Thomas Wiesner; Rajmohan Murali; Isabella Fried; Lorenzo Cerroni; Klaus Busam; Heinz Kutzner; Boris C Bastian Journal: Am J Surg Pathol Date: 2012-06 Impact factor: 6.394
Authors: Mohamed H Abdel-Rahman; Robert Pilarski; Colleen M Cebulla; James B Massengill; Benjamin N Christopher; Getachew Boru; Peter Hovland; Frederick H Davidorf Journal: J Med Genet Date: 2011-09-22 Impact factor: 6.318
Authors: Klaus J Busam; Joanne Sung; Thomas Wiesner; Andreas von Deimling; Achim Jungbluth Journal: Am J Surg Pathol Date: 2013-02 Impact factor: 6.394
Authors: Iwei Yeh; Thaddeus W Mully; Thomas Wiesner; Swapna S Vemula; Sonia A Mirza; Alyssa J Sparatta; Timothy H McCalmont; Boris C Bastian; Philip E LeBoit Journal: Am J Surg Pathol Date: 2014-08 Impact factor: 6.394
Authors: Thomas Wiesner; Anna C Obenauf; Rajmohan Murali; Isabella Fried; Klaus G Griewank; Peter Ulz; Christian Windpassinger; Werner Wackernagel; Shea Loy; Ingrid Wolf; Agnes Viale; Alex E Lash; Mono Pirun; Nicholas D Socci; Arno Rütten; Gabriele Palmedo; David Abramson; Kenneth Offit; Arthur Ott; Jürgen C Becker; Lorenzo Cerroni; Heinz Kutzner; Boris C Bastian; Michael R Speicher Journal: Nat Genet Date: 2011-08-28 Impact factor: 38.330